Analysts See Provention Bio Inc. (PRVB) Rising 61.44%

    Publicly-traded company Provention Bio Inc. (NASDAQ:PRVB) had a closing price of $8.29 yesterday. Meanwhile, the average 12-month price target from Wall Street analysts is currently $21.50, this means that the stock is underpriced by 61.44%. In the past 52 weeks the company’s stock price has moved within the range of $1.52 to $22.82.

    This particular stock’s 5-day moving average is 7.08, its 20-day moving average is 6.47 and its 100-day moving average is 9.29. Provention Bio Inc. (PRVB) currently has 44.59M shares outstanding, which means that its market capitalization is $369.65M.

    The Details: Provention Bio Inc. (PRVB) Financial Health

    We can also see what the current Return on Assets is for the company, which is a percentage that lets us know how well it is utilizing its net assets to turn a profit. The lower the percentage, the worse the company is making use of its assets. At the moment, Provention Bio Inc. Return on Assets is -61.30%.

    What Does Wall Street Say about Company?

    When investors are considering buying a new stock, they often want to know the general Wall Street consensus on the company – by checking out the average analyst rating, for instance. At the moment, the average analyst rating for PRVB is Buy. Out of 3 total analysts who were surveyed, 0 rated it a sell, 0 rated it a underweight, 0 rated it an overweight, 0 rated it hold, and 3 rated it a Buy.

    Understanding Profitability at Provention Bio Inc. (PRVB)

    Checking out a public company’s Earnings per Share (EPS) is a smart way of assessing its profitability. In the most recent financial results released by Provention Bio Inc., for the quarter ending on 12/2019, the company posted EPS of -0.27. The average estimate of Wall Street analysts had projected -0.25.